Research Article: Comprehensive Analysis of NABP as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma
Abstract:
Primary liver cancer is a highly malignant tumour that has posed a serious threat to human health for a long time. According to some research statistics, it ranks sixth in the incidence of liver cancer and third in the mortality of liver cancer. Hepatocellular carcinoma (HCC), which is also referred to as LIHC (liver hepatocellular carcinoma), accounts for % of cases.– The most important and common cause of HCC is infection with the hepatitis B virus, which is predicted to account for approximately half of all cases. Surgical resection, liver transplantation, radiotherapy, and chemotherapy are the primary treatment options for many liver cancer patients. Bioavailable multikinase inhibitors (MKIs), particularly regorafenib, benefit the survival of HCC patients., As the effectiveness of immunotherapy has been proven in other solid tumours, it is gradually being used in liver cancer. However, HCC patients treated only with immune checkpoint inhibitors (ICIs) do not respond well to therapy., The PD-L inhibitor atezolizumab plus the antiangiogenic agent bevacizumab has been proven to have better treatment outcomes.– Based on these therapeutic approaches, identifying more effective biomarkers and implementing combination therapy may benefit patients with liver cancer more.
Introduction:
Primary liver cancer is a highly malignant tumour that has posed a serious threat to human health for a long time. According to some research statistics, it ranks sixth in the incidence of liver cancer and third in the mortality of liver cancer. Hepatocellular carcinoma (HCC), which is also referred to as LIHC (liver hepatocellular carcinoma), accounts for % of cases. – The most important and common cause of HCC is infection with the hepatitis B virus, which is predicted to account for approximately half of all…
Read more